November 22nd, 2021 · Common Contracts · 1000 similar Bleuacacia LTD – INVESTMENT MANAGEMENT TRUST AGREEMENT This Investment Management Trust Agreement (this “Agreement”) is made effective as of November 17, 2021, by and between bleuacacia ltd, a Cayman Islands exempted company (the “Company”), and Continental Stock Transfer & Trust Company, a New York corporation (the “Trustee”).
This Investment Management Trust Agreement (this “Agreement”) is made effective as of November 17, 2021, by and between bleuacacia ltd, a Cayman Islands exempted company (the “Company”), and Continental Stock Transfer & Trust Company, a New York corporation (the “Trustee”).
October 10th, 2007 · Common Contracts · 1000 similar Macrochem Corp – SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of October 10, 2007, among MacroChem Corporation, a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
This Securities Purchase Agreement (this “Agreement”) is dated as of October 10, 2007, among MacroChem Corporation, a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
May 27th, 2020 · Common Contracts · 1000 similar Longview Acquisition Corp. – INDEMNITY AGREEMENT THIS INDEMNITY AGREEMENT (this “Agreement”) is made as of May 20, 2020, by and between Longview Acquisition Corp., a Delaware corporation (the “Company”), and __________________ (“Indemnitee”).
THIS INDEMNITY AGREEMENT (this “Agreement”) is made as of May 20, 2020, by and between Longview Acquisition Corp., a Delaware corporation (the “Company”), and __________________ (“Indemnitee”).
July 17th, 2019 · Common Contracts · 1000 similar SC Health Corp – REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of July 11, 2019, is made and entered into by and among SC Health Corporation, a Cayman Islands exempted company (the “Company”), SC Health Holdings Limited, a Cayman Islands exempted company (the “Sponsor”), and the undersigned parties listed under Holders on the signature page hereto (each such party, together with the Sponsor and any person or entity who hereafter becomes a party to this Agreement pursuant to Section 5.2 of this Agreement, a “Holder” and collectively the “Holders”).
THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of July 11, 2019, is made and entered into by and among SC Health Corporation, a Cayman Islands exempted company (the “Company”), SC Health Holdings Limited, a Cayman Islands exempted company (the “Sponsor”), and the undersigned parties listed under Holders on the signature page hereto (each such party, together with the Sponsor and any person or entity who hereafter becomes a party to this Agreement pursuant to Section 5.2 of this Agreement, a “Holder” and collectively the “Holders”).
September 17th, 2021 · Common Contracts · 1000 similar CIIG Capital Partners II, Inc. – WARRANT AGREEMENT between CIIG CAPITAL PARTNERS II, INC. and CONTINENTAL STOCK TRANSFER & TRUST COMPANY THIS WARRANT AGREEMENT (this “Agreement”), dated as of September 14, 2021, is by and between CIIG Capital Partners II, Inc., a Delaware corporation (the “Company”), and Continental Stock Transfer & Trust Company, a New York corporation, as warrant agent (the “Warrant Agent”, also referred to herein as the “Transfer Agent”).
THIS WARRANT AGREEMENT (this “Agreement”), dated as of September 14, 2021, is by and between CIIG Capital Partners II, Inc., a Delaware corporation (the “Company”), and Continental Stock Transfer & Trust Company, a New York corporation, as warrant agent (the “Warrant Agent”, also referred to herein as the “Transfer Agent”).
May 31st, 2002 · Common Contracts · 1000 similar Enterasys Networks Inc /De/ – and
November 22nd, 2021 · Common Contracts · 1000 similar Bleuacacia LTD – 24,000,000 Units bleauacacia ltd UNDERWRITING AGREEMENT bleuacacia ltd, a Cayman Islands exempted company (the “Company”), proposes, subject to the terms and conditions stated in this agreement (the “Agreement”), to sell to you and, as applicable, to the several underwriters named in Schedule I hereto (collectively, the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, 24,000,000 units (the “Units”) of the Company (said units to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to 3,600,000 additional units to cover over-allotments, if any (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule I other than you, the term Representatives as used herein shall mean you, as Underwriters, and the term Underwriter shall mean either the singular o
bleuacacia ltd, a Cayman Islands exempted company (the “Company”), proposes, subject to the terms and conditions stated in this agreement (the “Agreement”), to sell to you and, as applicable, to the several underwriters named in Schedule I hereto (collectively, the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, 24,000,000 units (the “Units”) of the Company (said units to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to 3,600,000 additional units to cover over-allotments, if any (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule I other than you, the term Representatives as used herein shall mean you, as Underwriters, and the term Underwriter shall mean either the singular o
November 9th, 2021 · Common Contracts · 1000 similar Novanta Inc – THIRD AMENDMENT TO THIRD AMENDED AND RESTATED CREDIT AGREEMENT
May 11th, 2021 · Common Contracts · 1000 similar Oaktree Acquisition Corp. III – WARRANT AGREEMENT between OAKTREE ACQUISITION CORP. III and CONTINENTAL STOCK TRANSFER & TRUST COMPANY THIS WARRANT AGREEMENT (this “Agreement”), dated as of [•], 2021, is by and between Oaktree Acquisition Corp. III, a Cayman Islands exempted company (the “Company”), and Continental Stock Transfer & Trust Company, a New York corporation, as warrant agent (the “Warrant Agent”, also referred to herein as the “Transfer Agent”).
THIS WARRANT AGREEMENT (this “Agreement”), dated as of [•], 2021, is by and between Oaktree Acquisition Corp. III, a Cayman Islands exempted company (the “Company”), and Continental Stock Transfer & Trust Company, a New York corporation, as warrant agent (the “Warrant Agent”, also referred to herein as the “Transfer Agent”).
November 12th, 2013 · Common Contracts · 990 similar Cubist Pharmaceuticals Inc – CONFIDENTIAL TREATMENT AMENDMENT NO. 1 TO CREDIT AGREEMENT, COLLATERAL AGREEMENT AND MASTER GUARANTEE AGREEMENT CREDIT AGREEMENT dated as of November 20, 2012 (this “Agreement”), among CUBIST PHARMACEUTICALS, INC., a Delaware corporation (the “Borrower”), the LENDERS party hereto, ROYAL BANK OF CANADA as an Issuing Bank and the Swingline Lender, and ROYAL BANK OF CANADA, as Administrative Agent.
CREDIT AGREEMENT dated as of November 20, 2012 (this “Agreement”), among CUBIST PHARMACEUTICALS, INC., a Delaware corporation (the “Borrower”), the LENDERS party hereto, ROYAL BANK OF CANADA as an Issuing Bank and the Swingline Lender, and ROYAL BANK OF CANADA, as Administrative Agent.
April 7th, 2021 · Common Contracts · 914 similar Fortegra Group, LLC – THE FORTEGRA GROUP, INC. (a Delaware corporation) [●] Shares of Common Stock UNDERWRITING AGREEMENT
April 14th, 2021 · Common Contracts · 876 similar Global SPAC Partners Co, – 16,000,000 Units Global SPAC Partners Co. UNDERWRITING AGREEMENT The undersigned Global SPAC Partners Co., a Cayman Islands exempted company (“Company”), hereby confirms its agreement with I-Bankers Securities, Inc. (hereinafter referred to as “you”, “I-Bankers”) as representative for and on behalf of itself and the other underwriters named on Schedule A hereto (the Representative and the other underwriters being collectively referred to herein as the “Underwriters” or, individually, an “Underwriter”):
The undersigned Global SPAC Partners Co., a Cayman Islands exempted company (“Company”), hereby confirms its agreement with I-Bankers Securities, Inc. (hereinafter referred to as “you”, “I-Bankers”) as representative for and on behalf of itself and the other underwriters named on Schedule A hereto (the Representative and the other underwriters being collectively referred to herein as the “Underwriters” or, individually, an “Underwriter”):
March 30th, 2017 · Common Contracts · 791 similar Tonix Pharmaceuticals Holding Corp. – UNDERWRITING AGREEMENT The undersigned, Tonix Pharmaceuticals Holding Corp., a corporation formed under the laws of the State of Nevada (collectively with its subsidiaries and affiliates, including, without limitation, all entities disclosed or described in the Registration Statement (as hereinafter defined) as being subsidiaries or affiliates of Tonix Pharmaceuticals Holding Corp., the “Company”), hereby confirms its agreement (this “Agreement”) with Aegis Capital Corp. (hereinafter referred to as “you” (including its correlatives) or the “Representative”) and with the other underwriters named on Schedule 1 hereto for which the Representative is acting as representative (the Representative and such other underwriters being collectively called the “Underwriters” or, individually, an “Underwriter”) as follows:
The undersigned, Tonix Pharmaceuticals Holding Corp., a corporation formed under the laws of the State of Nevada (collectively with its subsidiaries and affiliates, including, without limitation, all entities disclosed or described in the Registration Statement (as hereinafter defined) as being subsidiaries or affiliates of Tonix Pharmaceuticals Holding Corp., the “Company”), hereby confirms its agreement (this “Agreement”) with Aegis Capital Corp. (hereinafter referred to as “you” (including its correlatives) or the “Representative”) and with the other underwriters named on Schedule 1 hereto for which the Representative is acting as representative (the Representative and such other underwriters being collectively called the “Underwriters” or, individually, an “Underwriter”) as follows:
November 21st, 2019 · Common Contracts · 627 similar OptiNose, Inc. – OptiNose, Inc. UNDERWRITING AGREEMENT
February 14th, 2022 · Common Contracts · 617 similar byNordic Acquisition Corp – INVESTMENT MANAGEMENT TRUST AGREEMENT This Investment Management Trust Agreement (this “Agreement”) is made effective as of February 8, 2022, by and between byNordic Acquisition Corporation, a Delaware corporation (the “Company”), and Continental Stock Transfer & Trust Company, a New York limited trust company (the “Trustee”).
This Investment Management Trust Agreement (this “Agreement”) is made effective as of February 8, 2022, by and between byNordic Acquisition Corporation, a Delaware corporation (the “Company”), and Continental Stock Transfer & Trust Company, a New York limited trust company (the “Trustee”).
June 1st, 2020 · Common Contracts · 599 similar Mersana Therapeutics, Inc. – MERSANA THERAPEUTICS, INC. 8,000,000 Shares of Common Stock, par value $0.0001 per share Underwriting Agreement Mersana Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representative (the “Representatives”), an aggregate of 8,000,000 shares of common stock, par value $0.0001 per share, of the Company (the “Underwritten Shares”) and, at the option of the Underwriters, up to an additional 1,200,000 shares of common stock of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares”. The shares of common stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock”.
Mersana Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representative (the “Representatives”), an aggregate of 8,000,000 shares of common stock, par value $0.0001 per share, of the Company (the “Underwritten Shares”) and, at the option of the Underwriters, up to an additional 1,200,000 shares of common stock of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares”. The shares of common stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock”.
June 10th, 2011 · Common Contracts · 467 similar Ness Technologies Inc – AGREEMENT AND PLAN OF MERGER among JERSEY HOLDING CORPORATION, JERSEY ACQUISITION CORPORATION and NESS TECHNOLOGIES, INC. Dated as of June 10, 2011 AGREEMENT AND PLAN OF MERGER, dated as of June 10, 2011 (the "Agreement"), among Jersey Holding Corporation, a Delaware corporation ("Parent"), Jersey Acquisition Corporation, a Delaware corporation and a direct wholly owned subsidiary of Parent ("Merger Sub"), and Ness Technologies, Inc., a Delaware corporation (the "Company").
AGREEMENT AND PLAN OF MERGER, dated as of June 10, 2011 (the "Agreement"), among Jersey Holding Corporation, a Delaware corporation ("Parent"), Jersey Acquisition Corporation, a Delaware corporation and a direct wholly owned subsidiary of Parent ("Merger Sub"), and Ness Technologies, Inc., a Delaware corporation (the "Company").
December 13th, 2021 · Common Contracts · 428 similar Sculptor Acquisition Corp I – REGISTRATION AND SHAREHOLDER RIGHTS AGREEMENT THIS REGISTRATION AND SHAREHOLDER RIGHTS AGREEMENT (this “Agreement”), dated as of December 8, 2021, is made and entered into by and among Sculptor Acquisition Corp I, a Cayman Islands exempted company (the “Company”), Sculptor Acquisition Sponsor I, a Cayman Islands limited liability company (the “Sponsor”), and the undersigned parties listed under Holder on the signature page hereto (each such party, together with the Sponsor and any person or entity who hereafter becomes a party to this Agreement pursuant to Section 6.2 of this Agreement, a “Holder” and collectively the “Holders”).
THIS REGISTRATION AND SHAREHOLDER RIGHTS AGREEMENT (this “Agreement”), dated as of December 8, 2021, is made and entered into by and among Sculptor Acquisition Corp I, a Cayman Islands exempted company (the “Company”), Sculptor Acquisition Sponsor I, a Cayman Islands limited liability company (the “Sponsor”), and the undersigned parties listed under Holder on the signature page hereto (each such party, together with the Sponsor and any person or entity who hereafter becomes a party to this Agreement pursuant to Section 6.2 of this Agreement, a “Holder” and collectively the “Holders”).
April 12th, 2017 · Common Contracts · 426 similar Angiodynamics Inc – Underwriting Agreement The stockholders named in Schedule II hereto (the “Selling Stockholders”) of AngioDynamics, Inc., a Delaware corporation (the “Company”), propose, subject to the terms and conditions stated herein, to sell to Barclays Capital Inc. as set forth in Schedule I hereto (the “Underwriters,” which term shall also include any underwriter substituted as hereinafter provided in Section 10 hereof, and to the extent there is only a single underwriter, the term “Underwriters” shall be deemed to refer to the single Underwriter, mutatis mutandis) an aggregate of 2,350,000 shares (the “Shares”) of Common Stock, par value $0.01 (“Stock”) of the Company.
The stockholders named in Schedule II hereto (the “Selling Stockholders”) of AngioDynamics, Inc., a Delaware corporation (the “Company”), propose, subject to the terms and conditions stated herein, to sell to Barclays Capital Inc. as set forth in Schedule I hereto (the “Underwriters,” which term shall also include any underwriter substituted as hereinafter provided in Section 10 hereof, and to the extent there is only a single underwriter, the term “Underwriters” shall be deemed to refer to the single Underwriter, mutatis mutandis) an aggregate of 2,350,000 shares (the “Shares”) of Common Stock, par value $0.01 (“Stock”) of the Company.
October 30th, 2018 · Common Contracts · 419 similar Clementia Pharmaceuticals Inc. – 5,300,000 Shares CLEMENTIA PHARMACEUTICALS INC. COMMON SHARES UNDERWRITING AGREEMENT The undersigned understands that Morgan Stanley & Co. LLC (“Morgan Stanley”) and Leerink Partners LLC (“Leerink” and together with Morgan Stanley, the “Representatives”) propose to enter into an Underwriting Agreement (the “Underwriting Agreement”) with Clementia Pharmaceuticals, Inc., a corporation incorporated under the Canada Business Corporations Act (the “Company”), pursuant to a Registration Statement on Form F-3 (File No. 333-227726) (the “Registration Statement”), providing for the public offering (the “Public Offering”) by the several Underwriters, including the Representatives (the “Underwriters”), of common shares (the “Shares”) of the Company (the “Common Shares”).
The undersigned understands that Morgan Stanley & Co. LLC (“Morgan Stanley”) and Leerink Partners LLC (“Leerink” and together with Morgan Stanley, the “Representatives”) propose to enter into an Underwriting Agreement (the “Underwriting Agreement”) with Clementia Pharmaceuticals, Inc., a corporation incorporated under the Canada Business Corporations Act (the “Company”), pursuant to a Registration Statement on Form F-3 (File No. 333-227726) (the “Registration Statement”), providing for the public offering (the “Public Offering”) by the several Underwriters, including the Representatives (the “Underwriters”), of common shares (the “Shares”) of the Company (the “Common Shares”).
March 3rd, 2021 · Common Contracts · 401 similar TCG Growth Opportunities Corp. – REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of [ ], 2021, is made and entered into by and among TCG Growth Opportunities Corp., a Delaware corporation (the “Company”), TCG Growth Opportunities Holdings LLC, a Delaware limited liability company (the “Sponsor”), and the undersigned parties listed under Holder on the signature page hereto (each such party, together with the Sponsor, members of the Sponsor and any person or entity who hereafter becomes a party to this Agreement pursuant to Section 6.2 of this Agreement, a “Holder” and collectively the “Holders”).
THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of [ ], 2021, is made and entered into by and among TCG Growth Opportunities Corp., a Delaware corporation (the “Company”), TCG Growth Opportunities Holdings LLC, a Delaware limited liability company (the “Sponsor”), and the undersigned parties listed under Holder on the signature page hereto (each such party, together with the Sponsor, members of the Sponsor and any person or entity who hereafter becomes a party to this Agreement pursuant to Section 6.2 of this Agreement, a “Holder” and collectively the “Holders”).
June 24th, 2020 · Common Contracts · 400 similar Iqvia Holdings Inc. – INDENTURE Dated as of June 24, 2020 among IQVIA Inc., as Issuer, the Guarantors party hereto and U.S. Bank National Association, as Trustee 2.875% SENIOR NOTES DUE 2028 INDENTURE, dated as of June 24, 2020, among IQVIA Inc., a Delaware corporation, each Guarantor (as defined herein) and U.S. Bank National Association, as Trustee.
INDENTURE, dated as of June 24, 2020, among IQVIA Inc., a Delaware corporation, each Guarantor (as defined herein) and U.S. Bank National Association, as Trustee.
February 5th, 2009 · Common Contracts · 380 similar Rxi Pharmaceuticals Corp – REGISTRATION RIGHTS AGREEMENT REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of the 30th day of January 2009 (this “Agreement”) between YA GLOBAL MASTER SPV LTD., a Cayman Islands exempt limited partnership (the “Investor”), and RXI PHARMACEUTICALS CORPORATION, a corporation organized and existing under the laws of the State of Delaware (the “Company”).
REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of the 30th day of January 2009 (this “Agreement”) between YA GLOBAL MASTER SPV LTD., a Cayman Islands exempt limited partnership (the “Investor”), and RXI PHARMACEUTICALS CORPORATION, a corporation organized and existing under the laws of the State of Delaware (the “Company”).
June 16th, 2010 · Common Contracts · 374 similar Aeterna Zentaris Inc. – SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of June 15, 2010, between Æterna Zentaris Inc., a Canadian corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
This Securities Purchase Agreement (this “Agreement”) is dated as of June 15, 2010, between Æterna Zentaris Inc., a Canadian corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
July 31st, 2009 · Common Contracts · 370 similar Rxi Pharmaceuticals Corp – SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of July 30, 2009, between RXi Pharmaceuticals Corporation., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
This Securities Purchase Agreement (this “Agreement”) is dated as of July 30, 2009, between RXi Pharmaceuticals Corporation., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
July 19th, 2004 · Common Contracts · 341 similar Novavax Inc – SECURITIES PURCHASE AGREEMENT SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of July 16, 2004 by and among Novavax, Inc., a Delaware corporation, with headquarters located at 8320 Guilford Road, Suite C, Columbia, Maryland 21046 (the “Company”), and the investors listed on the Schedule of Buyers attached hereto (individually, a “Buyer” and collectively, the “Buyers”).
SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of July 16, 2004 by and among Novavax, Inc., a Delaware corporation, with headquarters located at 8320 Guilford Road, Suite C, Columbia, Maryland 21046 (the “Company”), and the investors listed on the Schedule of Buyers attached hereto (individually, a “Buyer” and collectively, the “Buyers”).
June 8th, 2005 · Common Contracts · 334 similar Teco Energy Inc – TECO ENERGY, INC. Floating Rate Notes Due 2010 REGISTRATION RIGHTS AGREEMENT TECO Energy, Inc., a Florida corporation (the “Company”), proposes to issue and sell to UBS Securities LLC, Citigroup Global Markets Inc., Morgan Stanley & Co. Incorporated, BNP Paribas Securities Corp, BNY Capital Markets, Inc. and SG Americas Securities, LLC (the “Initial Purchasers”), upon the terms set forth in a purchase agreement of dated June 2, 2005 (the “Purchase Agreement”), an aggregate of U.S. $100,000,000 principal amount of Floating Rate Notes due 2010 (the “Initial Securities”). The Initial Securities will be issued pursuant to an Indenture, dated as of August 17, 1998 (the “Indenture”), among the Company and The Bank of New York, as trustee (the “Trustee”). As an inducement to the Initial Purchasers to enter into the Purchase Agreement, the Company agrees with the Initial Purchasers, for the benefit of the Initial Purchasers and the holders of the Securities (as defined below) (collectively the “Holders”), as follows:
TECO Energy, Inc., a Florida corporation (the “Company”), proposes to issue and sell to UBS Securities LLC, Citigroup Global Markets Inc., Morgan Stanley & Co. Incorporated, BNP Paribas Securities Corp, BNY Capital Markets, Inc. and SG Americas Securities, LLC (the “Initial Purchasers”), upon the terms set forth in a purchase agreement of dated June 2, 2005 (the “Purchase Agreement”), an aggregate of U.S. $100,000,000 principal amount of Floating Rate Notes due 2010 (the “Initial Securities”). The Initial Securities will be issued pursuant to an Indenture, dated as of August 17, 1998 (the “Indenture”), among the Company and The Bank of New York, as trustee (the “Trustee”). As an inducement to the Initial Purchasers to enter into the Purchase Agreement, the Company agrees with the Initial Purchasers, for the benefit of the Initial Purchasers and the holders of the Securities (as defined below) (collectively the “Holders”), as follows:
March 2nd, 2017 · Common Contracts · 317 similar Paratek Pharmaceuticals, Inc. – Controlled Equity OfferingSM Sales Agreement Paratek Pharmaceuticals, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co. (the “Agent”), as follows:
Paratek Pharmaceuticals, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co. (the “Agent”), as follows:
June 17th, 2004 · Common Contracts · 314 similar BRP (Luxembourg) 4 S.a.r.l. – BOMBARDIER RECREATIONAL PRODUCTS INC. and the Guarantors Signatories Hereto 8 3/8% SENIOR SUBORDINATED NOTES DUE 2013 INDENTURE INDENTURE dated as of December 18, 2003 among Bombardier Recreational Products Inc., a Canadian corporation (the “Company”), the Guarantors signatories hereto and U.S. Bank National Association, as trustee (the “Trustee”).
INDENTURE dated as of December 18, 2003 among Bombardier Recreational Products Inc., a Canadian corporation (the “Company”), the Guarantors signatories hereto and U.S. Bank National Association, as trustee (the “Trustee”).
August 13th, 2019 · Common Contracts · 305 similar Ironwood Pharmaceuticals Inc – Credit Suisse Capital LLC c/o Credit Suisse Securities (USA) LLC New York, NY 10010 The purpose of this letter agreement (this “Confirmation”) is to confirm the terms and conditions of the call option transaction entered into between Credit Suisse Capital LLC (“Dealer”), represented by Credit Suisse Securities (USA) LLC (“Agent”) and Ironwood Pharmaceuticals, Inc. (“Counterparty”) as of the Trade Date specified below (the “Transaction”). This letter agreement constitutes a “Confirmation” as referred to in the ISDA Master Agreement specified below. This Confirmation shall replace any previous agreements with respect to the Transaction and serve as the final documentation for the Transaction.
The purpose of this letter agreement (this “Confirmation”) is to confirm the terms and conditions of the call option transaction entered into between Credit Suisse Capital LLC (“Dealer”), represented by Credit Suisse Securities (USA) LLC (“Agent”) and Ironwood Pharmaceuticals, Inc. (“Counterparty”) as of the Trade Date specified below (the “Transaction”). This letter agreement constitutes a “Confirmation” as referred to in the ISDA Master Agreement specified below. This Confirmation shall replace any previous agreements with respect to the Transaction and serve as the final documentation for the Transaction.
March 27th, 2015 · Common Contracts · 300 similar Novavax Inc – 24,137,931 Shares of Common Stock par value $0.01 3,620,689 Option Shares Novavax, Inc. UNDERWRITING AGREEMENT
May 10th, 2013 · Common Contracts · 290 similar Agenus Inc – LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT (this “Agreement”) dated as of April 15, 2013 (the “Effective Date”) among (a) SILICON VALLEY BANK, a California corporation with a loan production office located at 275 Grove Street, Suite 2-200, Newton, Massachusetts 02466 (“Bank”), and (b) AGENUS INC., a Delaware corporation (“Agenus”) and ANTIGENICS INC., a Massachusetts corporation (“Antigenics”) (Agenus and Antigenics are individually and collectively, jointly and severally, “Borrower”), provides the terms on which Bank shall lend to Borrower and Borrower shall repay Bank. The parties agree as follows:
THIS LOAN AND SECURITY AGREEMENT (this “Agreement”) dated as of April 15, 2013 (the “Effective Date”) among (a) SILICON VALLEY BANK, a California corporation with a loan production office located at 275 Grove Street, Suite 2-200, Newton, Massachusetts 02466 (“Bank”), and (b) AGENUS INC., a Delaware corporation (“Agenus”) and ANTIGENICS INC., a Massachusetts corporation (“Antigenics”) (Agenus and Antigenics are individually and collectively, jointly and severally, “Borrower”), provides the terms on which Bank shall lend to Borrower and Borrower shall repay Bank. The parties agree as follows:
June 16th, 2005 · Common Contracts · 255 similar Select Specialty Hospital Topeka Inc – 580,000,000 Tranche B Term Loan Facility and a $300,000,000 Revolving Credit Facility dated as of
December 20th, 2013 · Common Contracts · 253 similar Verastem, Inc. – VERASTEM, INC. Up to $35,000,000 of Shares of Common Stock (par value $0.0001 per share) Controlled Equity OfferingSM Sales Agreement Verastem, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co. (the “Agent”), as follows:
Verastem, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co. (the “Agent”), as follows:
February 26th, 2008 · Common Contracts · 247 similar Biogen Idec Inc. – BIOGEN IDEC INC. and THE BANK OF NEW YORK TRUST COMPANY, N.A., as Trustee INDENTURE Debt Securities Dated as of February 26, 2008 INDENTURE, dated as of February 26, 2008, by and between Biogen Idec Inc., a Delaware corporation, as Issuer (the “Company”), and The Bank of New York Trust Company, N.A., a national association, as Trustee (the “Trustee”).
INDENTURE, dated as of February 26, 2008, by and between Biogen Idec Inc., a Delaware corporation, as Issuer (the “Company”), and The Bank of New York Trust Company, N.A., a national association, as Trustee (the “Trustee”).